Notable Xarelto Lawsuit Claims Creates New Concern Regarding New-Generation Blood Thinner

February 25, 2016 – – BloodThinnerHelp.com reports on a markedly notable lawsuit filed against Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG in a Pennsylvania State Court. The lawsuit joins over 550 others from PA which have been consolidated by the Court of Common Pleas. Additionally, Xarelto is the subject of over 2,800 lawsuits consolidated to form MDL No. 2592 in Eastern Louisiana. This lawsuit, however, stands alone in its claims, making it important to observe. While thousands of Xarelto lawsuits have now been filed against the anticoagulant manufacturers regarding the sudden bleeding episodes associated with the drug, this one highlights a new concern: the once-daily dosage of the Xarelto, which is unlike any other blood thinner on the market today.

Most blood thinners available today require the user to ingest 2 pills daily to ensure that their body is properly medicated for a full 24-hours. Details found within this particular suit note Xarelto’s different recommended once-daily dosage, and allege that it is ineffective for an entire 24-hour period of time. The plaintiff claims to have supporting evidence of this problem, as he suddenly suffered a stroke just four days after starting to take Xarelto. He was using the drug specifically to prevent strokes, as he was deemed at increased risk for them to occur due to his atrial fibrillation.

Xarelto’s dosage has been brought into question, not only due to its one pill per day recommendation, but also because the pill itself is advertised as a one-size-fits-all dosage. No matter the weight or size of the patient taking the blood thinner, this dosing remains the same. After suffering a stroke, the plaintiff, in this case, filed a lawsuit on October 8, 2015. His lawsuit has garnered public attention and raised additional questions and safety concerns regarding Xarelto, which the plaintiff states not only neglected to prevent his stroke, but may have even caused it to occur.

Xarelto was approved by the U.S. Food and Drug Administration in 2011 to prevent strokes and blood clots for patients recovering from hip and knee replacement surgeries and deep vein thrombosis. These approved uses were later expanded to include treatment for patients with atrial fibrillation; a fairly common heart condition. Since its initial approval, Xarelto was given two black box warnings by the FDA. These warnings are the most severe product warnings possible to issue before removing the drug from the market fully.

As those involved in Xarelto lawsuit cases await their day in court, Attorney Joseph Osborne is working to help ensure that anyone who has used Xarelto and suffered from side effects that they attribute to the drug will be provided with the opportunity to explore their legal rights in full. He is currently offering free consultations to those who have been affected. These individuals may be entitled to significant compensation.

To request further Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008367